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Various studies and meta-analyses have suggested that 
in cases of left atrial thrombi in nonrheumatic atrial 
fibrillation (AF) patients, approximately 90% of them are 
located in the left atrial appendage (LAA).1 Patients are 
effectively protected from thromboembolism in this 
setting by anticoagulation therapy, shown to reduce the 
incidence by 60-70% with vitamin K antagonists and 
maybe more by the newer anticoagulants.2,3 However, 
anticoagulation therapy is limited by an increased risk of 
major bleeding, in addition to other hindrances, such as 
difficulty in monitoring anticoagulation therapy, several 
drug and food interactions for classical warfarin, or cost 
and bleeding issues with the newer drugs, all leading to 
limited use of anticoagulation in clinical practice with 
percentages reported at 30-50%.3-5 For these reasons, 
alternative device therapies with occlusion of the LAA, 
considered the most common source of thromboembolism 
in this cohort, have been recently pursued.6-10  
In the European PLAATO (Percutaneous Left Atrial 
Appendage Transcatheter Occlusion) study,6 the first 
device ever used for this purpose, which, however, was 
subsequently withdrawn, had an initial implant success 
rate of 90% among 180 patients. However, there was a 
1.1% mortality (2 patients) related to the procedure, while 
6 cases of cardiac tamponade also occurred (3.3%). In 
two cases, surgical drainage of the tamponade was 
necessary (1.1%). In one patient the device embolized 
into the aorta after its release (0.6%) (at the end 
successfully snared and replaced). During follow-up, 3 
strokes occurred (2.3% per year). The expected incidence 
of stroke according to the CHADS2-Score was 6.6% per 
year. The trial was halted prematurely during the follow-
up phase, allegedly for financial considerations. 
In the initial experience with a newer nitinol device, 
the WATCHMAN Left Atrial Appendage System 
(Atritech Inc., Plymouth, Minnesota),7 among 66 patients 
out of 75 (88%) who underwent successful device 
implantation, at 45 days, 93% (54 of 58) of the devices 
showed successful sealing of LAA. Two patients 
experienced device embolization, both successfully 
retrieved percutaneously. No embolizations occurred in 
53 patients enrolled after modification of the fixation 
barbs. There were 2 cardiac tamponades, 1 air embolism, 
and 1 delivery wire fracture. Four patients developed 
thrombus on the device at 6 months that resolved with 
additional anticoagulation. Two patients experienced 
transient ischemic attack, 1 without visible thrombus. 
There were 2 non-device-related deaths; no strokes 
occurred during follow-up despite that >90% of patients 
discontinued anticoagulation.  
In the most notable randomized study using a second 
generation Watchman device, the Watchman Left Atrial 
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Appendage System for Embolic Protection in Patients 
With AF (PROTECT AF) randomized trial,8 LAA closure 
was compared against warfarin in AF patients with 
CHADS2 score >1. The study showed that LAA closure 
was noninferior to warfarin therapy for the prevention of 
stroke/systemic embolism/cardiovascular death (primary 
efficacy end-point), but there was a significantly higher 
risk of complications, predominantly pericardial effusion 
and procedural stroke related to air embolism. 
Specifically, adult patients with non-valvular atrial 
fibrillation were eligible for inclusion in this trial if they 
had at least one of the following: previous stroke or 
transient ischemic attack, congestive heart failure, 
diabetes, hypertension, or were 75 years or older. A total 
of 707 eligible patients were randomly assigned in a 2:1 
ratio to percutaneous closure of the LAA and subsequent 
discontinuation of warfarin (intervention group; n=463) 
or to warfarin treatment with a target international 
normalised ratio between 2.0 and 3.0 (control group; 
n=244). At follow-up, the primary efficacy event rate was 
3.0 per 100 patient-years in the intervention group and 
4.9 per 100 patient-years in the control group (rate ratio 
[RR] 0.62). The probability of non-inferiority of the 
intervention was more than 99.9%. Primary safety events 
were more frequent in the intervention group than in the 
control group (7.4 per 100 patient-years, vs 4.4 per 100 
patient-years; RR 1.69). The authors concluded that their 
strategy for closing the LAA was non-inferior to warfarin 
therapy in terms of the primary efficacy endpoint of all 
stroke, cardiovascular death, and systemic embolism. 
Although there was a higher initial safety event rate for 
device implantation, they alleged that these adverse 
events were without long-term sequelae for most patients 
and that closure of the LAA might provide an alternative 
strategy to chronic warfarin therapy for stroke 
prophylaxis in patients with nonvalvular atrial fibrillation. 
 
Further analysis of the PROTECT AF study cohort 
(n=452) and of a subsequent registry population (n=460) 
undergoing Watchman implantation,9 indicated a 
significant reduction in the rate of procedure- or device-
related safety events within 7 days of the procedure with 
increased operator experience, with 7.7% and 3.7% of 
patients, respectively, experiencing events (a relative 
reduction of 56%; P=0.007), and between the first and 
second halves of the PROTECT AF study and the registry 
population, with 10.0%, 5.5%, and 3.7% of patients, 
respectively, experiencing events (P=0.006). 
 
In a recent study with use of a novel device 
(Amplatzer cardiac plug),10 the success rate was 96% 
among the 137 patients in whom it was attempted, but the 
rate of serious complications culminated to 7%, including 
ischemic stroke (n=3), device embolization (n=2), (both 
percutaneously recaptured) and clinically significant 
pericardial effusions (n=5); there were also minor 
complications noted in 5%, including insignificant 
pericardial effusions (n=4), transient myocardial ischemia 
(n=2), and loss of the implant in the venous system (n=1).  
In conclusion, percutaneous LAA closure with current 
devices is feasible and may be non-inferior to 
anticoagulation therapy in patients with AF, however, 
current device technology and operator experience leave 
much room for improvement and should be viewed with 
great caution due to significant complication rates that 
this procedure confers even at most experienced centers. 
Another source of concern is the device potential 
thrombogenicity, especially when not well seated in the 
appendage, as well as the non-LAA sources of thrombi, 
such as the recently described left atrial pouch, not 
addressed by this strategy.11  
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Pulmonary Hypertension (PH) is defined as an 
increase in mean pulmonary arterial pressure (PAP) ≥25 
mmHg at rest as assessed by right heart catheterization 
(RHC). As stated in the European Society of Cardiology 
(ESC) 2009 guidelines, it can be classified into 5 main 
categories, presented in Table 1. Pulmonary arterial 
hypertension is a rare disease with a prevalence of 15 
cases /million adult population and an incidence of 2.4 
cases/million adult population/year.1,2 The 
pathophysiology of PH is complex and it has not been 
elucidated in detail since it involves various biochemical 
pathways and cell types. Vasoconstriction, remodeling 
with extensive proliferation of the vessel wall cells 
causing progressive obstruction, inflammation and 
thrombosis have been implicated. Structural or functional 
abnormalities of potassium channels in the smooth 
muscle cells and endothelial dysfunction characterized by 
impaired nitric oxide (NO) and prostacyclin production or 
increased expression of thromboxane A2 and endothelin-
1are thought to underlie the cellular changes.3  
Although groups two and three account for the 
majority of the cases, the trials testing and validating 
therapeutic options involve mostly patients with group 
one PH (Pulmonary Arterial Hypertension-PAH). Apart 
from conventional therapy including diuretics, oral 
anticoagulants, calcium channel blockers in case of 
established vasoreactivity, digoxin, oxygen 
administration and exercise –rehabilitation programs, 
specific drugs have emerged and gradually find their 
place in the management of PAH during the last decade. 
Prostanoids such as intravenous (IV) epoprostenol, 
iloprost inhaled and IV and treprostinil subcutaneously 
(SC) or IV have been established agents in the 
management of PAH, improving performance ability and 
survival (epoprostenol). Beraprost has shown promising 
albeit short –term results in the ALPHABET trial.4-10 
Phosphodiesterase (PDE) type-5 inhibitors (sildenafil, 
tadalafil) and endothelin receptor antagonists (bosentan, 
ambrisentan) improve exercise capacity and 
hemodynamic parameters and are widely used in the 
treatment of PAH.11-16 Sitaxentan demonstrated 
favourable results initially 17, 18 but was subsequently 
withdrawn in early 2011 due to a few cases of fatal 
hepatic toxicity considered to be idiosyncratic, 
unpredictable and thus unpreventable. 
 
Table 1. Classification of Pulmonary Hypertension  
 
Pulmonary Arterial 
Hypertension (PAH) 
PH due to Lung Diseases 
&/or Hypoxia 
Idiopathic (IPAH) Chronic obstructive pulmonary 
disease (COPD)
Heritable/familial (FPAH) Interstitial lung disease
       BMPR2       ALK1, Endoglin 
       Unknown
Other pulmonary diseases with 
mixed restrictive & obstructive 
pattern 
Drug and toxin-induced Sleep disordered breathing
Associated with APAH Alveolar hyperventilation dis.
       Connective tissue disorders  Chronic exposure of high 
altitude 
       HIV infection Developmental abnormalities
       Portal hypertension  
       Congenital heart diseases Chronic Thromboembolic PH 
(CTEPH) 
       Schistosomiasis  
       Chronic hemolytic anemia PH with Indistinct, Multi-
factorial Mechanisms
Persistent PH of the newborn 
(PPHN)
Hematological dis. (e.g. myelo-
proliferative dis., splenectomy, 
hemoglobinopathies)  
Pulmonary Veno-Occlusive 
Disease (PVOD) & 
Pulmonary Capillary 
Systemic dis. (e.g. sarcoidosis, 
pulmonary Langerhans cell 
histocytosis, lymphangiomatosis) 
Metabolic dis. (e.g. glycogen 
storage disease, Gaucher’s 
disease, thyroid disorders) 
PH with Left Heart Disease 
Systolic dysfunction 
Diastolic dysfunction Others (e.g. tumoural 
obstruction, fibrosing 
mediastinitis, chronic renal 
failure & dialysis)
Valvular disease
 
ALK-1 = activin receptor-like kinase 1 gene; APAH = associated 
pulmonary arterial hypertension; BMPR2 = bone 
morphogenetic protein receptor, type 2; dis. = disorders; HIV = 
human immunodeficiency virus; PAH = pulmonary arterial 
hypertension; PH = pulmonary hypertension 
  
In spite of the remarkable progress in the management 
of PAH, the response cannot yet be characterized 
satisfactory. Moreover, the cost of specific treatment is 
still considerably high. Thus, the need for novel medical 
approaches is still present. New agents of the already 
used categories are tested. Macitentan, a novel endothelin 
(ET)-A/ET-B receptor antagonist, is being evaluated in 
